Use Of Anticancer Agents Research Articles

Study for Metabolism of Resistant Production in Anticancer drug Resistant Stomach Cancer Cell SNU-1

Development of drug resistance in tumors during treatment is a major factor limiting the clinical use of anticancer agents. When tumor cells acquire resistance to anticancer drug, they show cross-resistance to other antitumor agents. In the present study, SNU-1 cell was induced adriamycin 10-7 drug resistance, SNU-1/ADR, in vitro culture system. We got the doubling time and number for viability test during 96 hours by MTT assay. To investigate the cross resistance of various anticancer drugs in human stomach cancer cell SNU-1 and SNU-1/ADR, We compared IC50 (drug concentration of 50% reduction) and the relative resistance (RR). SNU-1/ADR was expressed multidrug resistant with vinblastine (RR;>31.62), vincristine (RR;29.50), dactinomycin (RR;21.37), epirubicin (RR;17.78), daunorubicin (RR;14.12), adriamycin (RR;7.76), and etoposide (RR;4.46), and other drugs, 5-fluorouracil, cisplatin, cyclophosphamide, methotrexate, and calarubicin, have not cross resistant with adriamycin. There was double minute chromosome in SNU-1/ADR by karyotyping although this change was not seen in SUN-1.

Hepatocellular carcinoma detected by iodized oil. Use of anticancer agents.

Transcatheter arterial embolization (TAE) was performed in 97 patients with hepatocellular carcinoma. Ethiodol (iodized oil) containing an anticancer drug was infused via the hepatic artery followed by Gelfoam particles. The Ethiodol emulsion was selectively retained in the tumor vessels and also remained in the small daughter nodules that could not be detected by angiography or computed tomography (CT) prior to TAE. Ethiodol remained in the tumor for more than 1 year. Following TAE, main tumors and small daughter nodules appeared as areas of markedly high density on CT. In most patients there was a reduction in the tumor size following TAE, and serum alpha-fetoprotein levels were reduced in all patients whose initial levels had exceeded 400 ng/ml. This method is considered to be effective not only for treatment of hepatic tumor but also useful for evaluation of post-TAE changes in the tumor and diagnosis of small daughter nodules, due to the long-term accumulation of Ethiodol in tumor vessels.

Significance of Laurén's classification in chemotherapy of gastric carcinoma.

The effects of anticancer agents were studied on the basis of survival rates following surgery for gastric carcinomas in different histologic types of Laurén's classification. It was revealed that Laurén's classification would provide an index to the use of anticancer agents to a certain extent. Anticancer agents were effective against diffuse gastric carcinoma, and should therefore be intensively used for treatment of this malignancy. For female patients with diffuse gastric carcinoma, careful selection of adequate anticancer agents is highly necessary. Anticancer agents were less effective against intestinal-type carcinoma, and it would therefore be necessary to use anticancer agents on the aged male patients with this malignancy by taking his age and side effects of the agents into consideration.

液性抵抗因子と癌に関する実験的研究

In order to see the effects of the drugs that elevate the serum properdin level on cancer-bearing animals, pantothenic acid (PaA), GABA, orotic acid (OrA), and vitamin K were given singly to mice bearing Ehrlich ascites carcinoma or these were concurrently administered with such anticancer drugs as Thio-TEPA and mitomycin C. The results of this study are given in the following.1. The administration of PaA or GABA alone not only prevents the fall in the serum properdin level but also prolongs the survival time of cancer bearing animals as compared with the control group not given such treatment. When these drugs are used concurrently with the anticancer agents mentioned above, the anticancer effect and the preventive effect on the diminution in the properdin level are further enhanced.2. Orotic acid and vitamin K have been found to have not much effect as to prolong the survival time nor to prevent the fall in the serum properdin level, whether given alone or concurrently with the anticancer agents.3. In the concurrent use of anticancer agents, it has been demonstrated that a greater effect of prolongation of survival time as well as prevention of the fall in the serum properdin level is attained when the properdin level-raising agent is administered prior to the administration of anticancer drug.4. Although properdin seems to be one of the anticancer factors, the anticancer effect of these drugs cannot be directly connected to the action to elevate properdin level.

EXPERIMENTAL USE OF ANTI-CANCER AGENTS IN THE PERITONEAL CAVITY.

Journal Article Experimental use of anti-cancer agents in the peritoneal cavity Get access B McKibbin, B McKibbin Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois Search for other works by this author on: Oxford Academic Google Scholar J-C Gazet J-C Gazet Department of Surgery, University of Illinois College of Medicine, Chicago, Illinois Search for other works by this author on: Oxford Academic Google Scholar British Journal of Surgery, Volume 51, Issue 9, September 1964, Pages 693–697, https://doi.org/10.1002/bjs.1800510912 Published: 06 December 2005